8 completed. 8 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Toxicity: new trials by email Literature Review of Toxicity trials Research Report on Toxicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy - Esophageal Squamous Cell Carcinoma, Efficacy | Phase 2 | Completed | Sun Yat-sen University | 170 | 2024-02-15 | 2026-08-03 |
| Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) Apatinib+IE, IE - Effect of Drug, Drug | Phase 2 | Completed | Peking University People's Hospital | 81 | 2022-03-01 | 2024-07-31 |
| Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma Apatinib, SHR-1210 - Progression-free Survival, Overall Survival | Phase 2 | Completed | Peking University People's Hospital | 43 | 2018-01-01 | 2020-05-19 |
| Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients metronomic XELOX, Classic XELOX, Blood samples for pharmacological studies - Clinical Response, Toxicity | Phase 2 | Completed | National Cancer Institute, Egypt | 70 | 2016-01-01 | 2020-06-11 |
| The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) Nab-paclitaxel - Esophageal Cancer, Toxicity | Phase 1 / Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 154 | 2014-10-01 | 2017-05-31 |
| Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer Oxaliplatine, Folinic acid, Irinotecan - Pancreatic Metastatic Cancer, Toxicity | Phase 2 | Completed | Institut Cancerologie de l'Ouest | 72 | 2014-07-31 | 2026-04-15 |
| Local Anaesthetics Toxicity and Intralipid® placebo, Intralipid® - Toxicity, Adverse Effects | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 16 | 2011-01-01 | 2016-12-21 |
| Exclusive Intraoperative Radiation Therapy for Breast Cancer 21 Gy radiation, 18 Gy radiation - Breast Neoplasms, Toxicity | Phase 2 / Phase 3 | Completed | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | 40 | 2009-04-01 | 2017-05-24 |
Osteosarcoma (2) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Neoplasm Metastasis (1)
Neoplasms (6) · Neoplasms by Site (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Neoplasms by Histologic Type (3) · Esophageal Diseases (2) · Head and Neck Neoplasms (2) · Neoplasms, Bone Tissue (2) · Neoplasms, Connective Tissue (2) · Neoplasms, Connective and Soft Tissue (2) · Sarcoma (2) · Breast Diseases (1) · Carcinoma (1)
Capecitabine (2) · Oxaliplatin (2) · apatinib (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Blood Specimen Collection (1) · Cisplatin (1) · Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Levobupivacaine (1) · Radiotherapy (1) · Ropivacaine (1) · camrelizumab (1) · soybean oil, phospholipid emulsion (1)
Peking University People's Hospital (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Assistance Publique - Hôpitaux de Paris (1) · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (1) · Institut Cancerologie de l'Ouest (1) · National Cancer Institute, Egypt (1) · Sun Yat-sen University (1)
China (3) · France (2) · Italy (1) · Netherlands (1)
Dan Benhamou (1) · Hanneke WM van Laarhoven, Prof.Dr. (1) · Hui Liu, Professor (1) · Marina Guenzi, MD (1) · Wei Guo, M.D.and Ph.D. (1)
PMID 27404223, PMID 30194205, PMID 32376724
2014 (1)